Rheumatoid arthritis: From synovium biology to cell-based therapy

• Published in: Cytotherapy (Oxford, England) Vol. 24; no. 4; pp. 365 - 375
• Main Authors: Debreova, Michaela, Culenova, Martina, Smolinska, Veronika, Nicodemou, Andreas, Csobonyeiova, Maria, Danisovic, Lubos
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.04.2022
• Subjects: Arthritis, Rheumatoid - therapy; autoimmunity; Biology; cell therapy; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells - physiology; mesenchymal/medicinal stem/signaling cells; rheumatoid arthritis; synovial biochemistry; Synovial Membrane - pathology; synovial biochemistry; autoimmunity; rheumatoid arthritis; cell therapy; mesenchymal/medicinal stem/signaling cells
• ISSN: 1465-3249; 1477-2566
• DOI: 10.1016/j.jcyt.2021.10.003

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the synovial joints and, if not treated properly, can lead to multiple progressive articular and extra-articular damage. Its pathogenesis is primarily associated with an inadequate immune response and dysregulated cytokine production. However, RA is also linked to disruption in oxygen metabolism, impaired redox signaling, acidosis and aberrant intercellular communication. Even though treatment modalities have made RA a manageable disease, a significant number of patients still do not respond satisfactorily or suffer considerably from the adverse events of conventional therapy. In recent years, cell-based strategies, especially the administration of the mesenchymal/medicinal stem/signaling cells (MSCs), have been proposed as a novel and very promising therapeutic approach. RA patients may benefit from the potent anti-inflammatory and immunomodulatory properties and tissue-repair potential of MSCs. Furthermore, the satisfactory safety profile of MSC therapy has been already demonstrated in several clinical studies. This review summarizes current understanding of the pathomechanism behind RA at the molecular and cellular level and focuses on MSC-based clinical research and applications of MSCs for RA treatment.